Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
145 hedge funds and large institutions have $1.35B invested in Alder Biopharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 64 increasing their positions, 31 reducing their positions, and 11 closing their positions.
264% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 11
106% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 31
24% more funds holding
Funds holding: 117 → 145 (+28)
23% more capital invested
Capital invested by funds: $1.1B → $1.35B (+$247M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
61% less call options, than puts
Call options by funds: $3.82M | Put options by funds: $9.72M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$33.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$20.8M |
| 5 |
SIG
Senator Investment Group
New York
|
+$19M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
151
HBK Investments
Dallas,
Texas
| – | -$282K | -11,500 | Closed |
|
|
QT
152
Quantbot Technologies
New York
| – | -$193K | -7,910 | Closed |
|
153
SG Americas Securities
New York
| – | -$179K | -7,323 | Closed |
|
|
PAM
154
Paradigm Asset Management
New York
| – | -$75.9K | -3,100 | Closed |
|
|
TRCT
155
Tower Research Capital (TRC)
New York
| – | -$60K | -2,434 | Closed |
|
ALDR Hedge Fund Activity: Q2 2016 in Review
145 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2016, worth a combined $1.35B — up 23% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ALDR positions and 11 closed out — a net gain of 29 holders — while 64 added to existing stakes and 31 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $33.1M. The largest seller was Point72 Asset Management, cutting an estimated $29.9M.
- 145 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2016, up from 117 in Q1 2016.
- Funds reported $1.35B of Alder Biopharmaceuticals stock for Q2 2016, up 23% quarter-over-quarter.
- 40 funds opened new Alder Biopharmaceuticals positions in Q2 2016 and 11 closed out, a net change of +29 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2016 was Wellington Management Group, an estimated $33.1M added.
- The largest Alder Biopharmaceuticals seller in Q2 2016 was Point72 Asset Management, an estimated $29.9M sold.
Based on aggregated 13F filings for Q2 2016.